NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS
https://doi.org/10.20996/1819-6446-2011-7-6-770-774
Abstract
The main objectives and strategies for treatment of atrial fibrillation (AF), one of the most common cardiac arrhythmia, are seen. A combination of strategies for heart rate control in patients with atrial fibrillation receiving rhythm-controling therapy is preferred at present, according to current guidelines. Amiodarone, one of the most effective anti-arrhythmic drugs with an extensive evidence base, remains the drug of reserve because of serious side effects. A new drug, dronedarone, has electrophysiological properties attributable to all four classes of antiarrhythmic drugs. According to meta-analysis of randomized clinical trials dronedarone is inferior to amiodarone in prevention of AF recurrences, but it is superior to amiodaron in safety. However , in 2011 dronedarone was included in the Food and Drug Administration (FDA) list of drugs that require further analysis in connection with appearance of the new information about its safety.
About the Authors
S. Yu. Martsevich
State Research Center for Preventive Medicine
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
Yu. V. Lukina
State Research Center for Preventive Medicine
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Stewart S., Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21
2. Nieuwlaat R., Capucci A., Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC members countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26:2422-34
3. Lip GYH, Tse H.-F. Management of atrial fibrillation. Review. Lancet 2007; 370: 604–18
4. Nabauer M., Gerth A., Limbourg T. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patients characteristics and initial management. Europace 2009; 11:423-34
5. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial fibrillation. Eur Heart J 2010; 31:967-75
6. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104-123
7. ESC guidelines 2010 on the management of atrial fibrillation. Eur Heart J 2010; 31(19): 2369–2429
8. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-867
9. Van Gelder I.C., Groenveld H.F., Crijns H.J.G.M. et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363–73
10. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–33
11. Hohnloser S.H., Kuck K.-H., Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789–94
12. Carlsson J., Miketic S., Windeler J. et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol 2003;41:1690–6
13. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: ООО Медицинское информационное агентство, 2005. - 1528 с.
14. Epstein A.E., Bigger J.T., Wyse D.G. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. Am Coll Cardiol 1991;18:14-9
15. The Cardiac Arrhythmia Suppression Trial II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33
16. McNamara R.L., Bass E.B., Miller M.R. et al. Management of new onset atrial fibrillation (evidence report/technology assessment). In: Agency for Healthcare Research and Quality. 2001, Publication No. AHRQ 01-E26.
17. Canadian Trial of Atrial Fibrillation (CTAF) Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913–20
18. Piccini J.P., Hasselblad V., Peterson E.D. et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54(12):1089-95
19. Hohnloser S.H., Crijns H.J.G.M., van Eickels M. for the ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 2009; 360: 668–78
20. Singh B.N., Connolly S.J., Crijns H.J.G.M. et al. for the EURIDIS and ADONIS Investigators. Dronеdarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. N Engl J Med 2007;357:987-99
21. Kober L., Torp-Pedersen C., McMurray J.J. et al. Increased mortality after dronedarone therapy for severe heart failure N Engl J Med 2008;358:2678-2687
22. Lehner J.P., Connolly S. Sanofi provides Multaq® Phase IIIb PALLAS trial update. Available on: http://www.europeanpharmaceuticalreview.com/8099/news/industry-news/sanofi-provides-multaq%c2%ae-phase-iiib-pallas-trial-update. Date of access 17.10.2011
23. Lowes R. New FDA Watch List Has Drug Making Fifth Straight Appearance. Available on: http://www.medscape.com/viewarticle/746530. Date of access 17.10.2011
24. Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS) between January — March 2011. Available on: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/UCM082196. Date of access: 17.10.2011
25. FDA U.S. Food and drug admimistration. U.S. department for Health and Human Services. Available on: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/Ad-verseDrugEffects/ucm258366.htm. Date of access 17.10.2011
26. FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. Available on: http://www.fda.gov/Drugs/DrugSafety/ucm264059.htm. Date of access 17.10.2011
27. Questions and answers on the review of Multaq (dronedarone). EMA/CHMP/706259/2011. Available on: http://www.ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. Date of access 17.10.2011
28. European Medicines Agency recommends restricting use of Multaq. EMA/CHMP/718819/2011. Available on: http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000025.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580028d98&jsenabled=true. Date of access 17.10.2011
Review
For citations:
Martsevich S.Yu., Lukina Yu.V. NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS. Rational Pharmacotherapy in Cardiology. 2011;7(6):770-774. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-6-770-774
Views: 963
Email this article 